On November 6th, the Trump administration reached an agreement with Novo Nordisk and Eli Lilly to substantially lower the cost of key GLP-1 medications, such as Wegovy and Zepbound, for millions, including Medicare recipients. These medications are used to treat conditions like obesity, diabetes, and heart disease, and the initiative is part of a broader effort to improve drug affordability and access through the TrumpRx public-private partnership.
The administration has announced plans to launch the TrumpRx website in early 2026, offering a direct-to-consumer platform for discounted medications. Patients using TrumpRx can expect to pay around $350 per month for injectable GLP-1 medications, with prices projected to decrease to $245 over the next two years for those paying out-of-pocket. Daily pill versions, pending FDA approval, are anticipated to start at $150 for initial doses.
Starting mid-2026, Medicare will cover injectable weight-loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound for eligible individuals with severe obesity or related health conditions, at a cost of $245 per month to Medicare and a maximum $50 monthly copay for recipients. State Medicaid programs will also have access to these prices. In addition, Eli Lilly and Novo Nordisk have announced reduced pricing on select diabetes, insulin, and migraine medications.
The agreement is part of a federal initiative to align U.S. drug prices with those in other developed nations, following an executive order issued in May 2025 for agencies to secure lower costs for consumers.
Employer Takeaway
TrumpRx may offer a practical solution for employees who do not qualify for their employer-sponsored health plans, particularly those seeking access to GLP-1 medications for weight management. As the program launches in 2026, it could become a helpful option for individuals managing obesity and related conditions.
While specific details about expanded coverage and access are still forthcoming, employers should stay informed as updates become available. Download the bulletin for more details.
